Tirzepatide Weight Loss Per Week: What the Data Shows

People starting tirzepatide want a weekly number. The honest answer requires some arithmetic and a disclaimer: weight loss on tirzepatide is not a straight line. It accelerates, stalls, and accelerates again as doses increase. This page converts the SURMOUNT-1 trial data into estimated weekly rates and explains why your scale will not cooperate with a neat weekly target.

Average Weekly Weight Loss from SURMOUNT-1

SURMOUNT-1 measured total percentage body weight lost over 72 weeks at three dose levels and placebo (PMID 35658024). Dividing total loss by 72 gives a crude weekly average. These numbers do not reflect what happens in any single week. They are arithmetic averages across the full treatment period.

Here is the math:

• 5 mg: 15.0% total / 72 weeks = 0.21% per week
• 10 mg: 19.5% total / 72 weeks = 0.27% per week
• 15 mg: 20.9% total / 72 weeks = 0.29% per week
• Placebo: 3.1% total / 72 weeks = 0.04% per week

For a 220-pound starting weight, 0.29% per week translates to roughly 0.64 pounds per week on average. That sounds modest. The reason is that the average flattens out periods of fast loss and periods of near-zero change into a single number. Actual weekly loss varies from week to week.

All three dose tracks start identically because every participant began at 2.5 mg for the first four weeks. The curves diverge once patients reach different maintenance doses. The 15 mg track shows a steeper middle section between weeks 12 and 36, when patients are escalating through higher doses and experiencing the strongest appetite suppression.

Why Weight Loss Is Not Linear

If tirzepatide delivered exactly 0.29% per week, every week, for 72 weeks, treatment planning would be simple. It does not work that way. Three distinct phases shape the trajectory.

Fast Early Weeks

The first four to eight weeks often produce the most noticeable changes. Appetite drops quickly after the first injection. Water weight shifts as carbohydrate intake falls and insulin levels change. Some patients lose 3 to 5 pounds in the first week alone. That pace is not sustainable. A portion of early weight loss is fluid redistribution, not fat loss.

Plateau Periods

Nearly every patient hits at least one plateau where the scale stops moving for two to four weeks despite continued medication use and dietary adherence. Metabolic adaptation reduces resting energy expenditure as body mass decreases. Hormonal shifts alter water retention. The body resists continued weight loss through compensatory mechanisms that evolved to prevent starvation.

Plateaus are not treatment failure. In the SURMOUNT trials, weight loss continued to accrue through week 60 before leveling off around week 72. Patients who interpret a two-week stall as evidence the drug stopped working and discontinue treatment lose the benefit of the subsequent months where additional weight would have been lost.

Dose Escalation Bumps

Each dose increase resets the appetite suppression effect. A patient adapted to 5 mg will experience renewed hunger reduction when moving to 7.5 mg. This produces a visible step-down on the weight chart. The pattern repeats at each escalation: a burst of loss over two to three weeks, followed by adaptation, followed by a slower rate until the next increase.

The standard protocol calls for 2.5 mg increments every four weeks. Reaching 15 mg takes a minimum of 20 weeks. Some prescribers hold patients at intermediate doses longer if side effects are problematic. There is no clinical advantage to rushing.

Factors That Affect Weekly Results

The SURMOUNT-1 averages are group means. Individual weekly results vary based on several factors that the trial controlled for or measured but that differ in real-world treatment.

Starting weight. A heavier starting weight means more absolute pounds lost per percentage point. A 300-pound patient losing 0.29% per week loses 0.87 pounds per week. A 180-pound patient losing the same percentage loses 0.52 pounds per week. The percentage rate is similar; the scale reads differently.

Caloric intake. SURMOUNT-1 participants received counseling targeting a 500 kcal/day deficit. Patients who eat closer to maintenance calories will lose weight more slowly even at full dose. Liquid calories, calorie-dense snacks, and alcohol can blunt the effect.

Physical activity. Exercise was encouraged but not standardized in the trials. Patients who add resistance training may see slower scale movement in some weeks because muscle gain offsets fat loss.

Sleep and stress. Chronic sleep deprivation and elevated cortisol increase hunger signaling independent of medication. Patients reporting poor results despite adherence often have unaddressed sleep or stress issues.

Medication adherence. Missing a weekly injection allows blood levels to drop and hunger to return. Tirzepatide has a half-life of approximately five days. Consistent weekly dosing is essential for the published results to apply.

For the full dose-response data and percentage thresholds at each dose, see our weight loss results page. Side effects that may affect adherence are covered on the side effects page.